These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
606 related articles for article (PubMed ID: 23950178)
1. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Richardson PG; Schlossman RL; Alsina M; Weber DM; Coutre SE; Gasparetto C; Mukhopadhyay S; Ondovik MS; Khan M; Paley CS; Lonial S Blood; 2013 Oct; 122(14):2331-7. PubMed ID: 23950178 [TBL] [Abstract][Full Text] [Related]
2. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J; Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120 [TBL] [Abstract][Full Text] [Related]
4. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707 [TBL] [Abstract][Full Text] [Related]
5. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544 [TBL] [Abstract][Full Text] [Related]
6. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Richardson PG; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Corrado C; Binlich F; San-Miguel JF Blood; 2016 Feb; 127(6):713-21. PubMed ID: 26631116 [TBL] [Abstract][Full Text] [Related]
7. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Laubach JP; Schjesvold F; Mariz M; Dimopoulos MA; Lech-Maranda E; Spicka I; Hungria VTM; Shelekhova T; Abdo A; Jacobasch L; Polprasert C; Hájek R; Illés Á; Wróbel T; Sureda A; Beksac M; Gonçalves IZ; Bladé J; Rajkumar SV; Chari A; Lonial S; Spencer A; Maison-Blanche P; Moreau P; San-Miguel JF; Richardson PG Lancet Oncol; 2021 Jan; 22(1):142-154. PubMed ID: 33301738 [TBL] [Abstract][Full Text] [Related]
9. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506 [TBL] [Abstract][Full Text] [Related]
10. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130 [TBL] [Abstract][Full Text] [Related]
11. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Wahaib K; Beggs AE; Campbell H; Kodali L; Ford PD Am J Health Syst Pharm; 2016 Apr; 73(7):441-50. PubMed ID: 27001985 [TBL] [Abstract][Full Text] [Related]
12. An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma. Hansen VL; Coleman M; Elkins S; Letzer JP; Levy MY; Seneviratne L; Rine J; White M; Kuriakose ET Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):400-407.e1. PubMed ID: 29656050 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768 [TBL] [Abstract][Full Text] [Related]
14. Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma. Greig SL Target Oncol; 2016 Feb; 11(1):107-14. PubMed ID: 26826025 [TBL] [Abstract][Full Text] [Related]
15. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjöberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F Oncologist; 2018 May; 23(5):631-636. PubMed ID: 29192015 [TBL] [Abstract][Full Text] [Related]
16. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. San-Miguel JF; Hungria VTM; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Na Nakorn T; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Salwender H; Sopala M; Redhu S; Paul S; Corrado C; Richardson PG Br J Haematol; 2017 Oct; 179(1):66-74. PubMed ID: 28653400 [TBL] [Abstract][Full Text] [Related]
17. The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. San-Miguel JF; Einsele H; Moreau P Adv Ther; 2016 Nov; 33(11):1896-1920. PubMed ID: 27677481 [TBL] [Abstract][Full Text] [Related]
18. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. Laubach JP; Tuchman SA; Rosenblatt JM; Mitsiades CS; Colson K; Masone K; Warren D; Redd RA; Grayson D; Richardson PG Blood Cancer J; 2021 Feb; 11(2):20. PubMed ID: 33563894 [TBL] [Abstract][Full Text] [Related]
19. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817 [TBL] [Abstract][Full Text] [Related]